亨迪药业
(301211)
| 流通市值：48.02亿 | | | 总市值：48.02亿 |
| 流通股本：4.18亿 | | | 总股本：4.18亿 |
| 报告期 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 |
| 公司类型 | 通用 | 通用 | 通用 | 通用 |
| 一、营业总收入 | 120,164,148.88 | 453,306,981.13 | 318,896,734.57 | 234,768,347.93 |
| 营业收入 | 120,164,148.88 | 453,306,981.13 | 318,896,734.57 | 234,768,347.93 |
| 二、营业总成本 | 119,112,800.57 | 439,869,142.57 | 318,613,218.65 | 228,432,709.66 |
| 营业成本 | 95,017,906.1 | 353,104,019.75 | 253,412,408.37 | 183,347,719.02 |
| 税金及附加 | 1,510,521.95 | 5,953,401.61 | 3,871,849.77 | 2,848,941.96 |
| 销售费用 | 5,102,851.18 | 20,636,163.31 | 16,393,666.49 | 11,773,604.17 |
| 管理费用 | 11,489,985.27 | 44,878,424.15 | 32,881,100.99 | 21,221,244.83 |
| 研发费用 | 5,497,981.82 | 25,180,041.91 | 20,201,406.64 | 15,252,609.56 |
| 财务费用 | 493,554.25 | -9,882,908.16 | -8,147,213.61 | -6,011,409.88 |
| 其中:利息费用 | 27,991.23 | 179,046.7 | 134,200.05 | 98,603.11 |
| 其中:利息收入 | 1,278,883.69 | 11,942,657.96 | 9,132,654.29 | 6,191,921.59 |
| 三、其他经营收益 | | | | |
| 加:公允价值变动收益 | 7,405,000 | 12,969,750.06 | 17,166,791.7 | 10,571,513.92 |
| 加:投资收益 | - | 16,165,741.61 | 4,715,230.83 | 4,282,814.18 |
| 资产处置收益 | - | 11,870.67 | 11,870.67 | 11,870.67 |
| 资产减值损失(新) | - | -4,346,634.5 | -2,029,344.38 | -2,029,344.38 |
| 信用减值损失(新) | -372,326.79 | -234,050.9 | 402,033.34 | -732,884.37 |
| 其他收益 | 2,166,410.71 | 3,851,104.29 | 3,154,650.99 | 1,996,637.25 |
| 四、营业利润 | 10,250,432.23 | 41,855,619.79 | 23,704,749.07 | 20,436,245.54 |
| 加:营业外收入 | - | 470,931.84 | 117,561.91 | 106,800 |
| 减:营业外支出 | 419.63 | 1,065,613.63 | 705,463.71 | 21,358.63 |
| 五、利润总额 | 10,250,012.6 | 41,260,938 | 23,116,847.27 | 20,521,686.91 |
| 减:所得税费用 | 1,031,948.95 | 6,350,339.21 | 2,183,492.08 | 1,974,604.33 |
| 六、净利润 | 9,218,063.65 | 34,910,598.79 | 20,933,355.19 | 18,547,082.58 |
| (一)按经营持续性分类 | | | | |
| 持续经营净利润 | 9,218,063.65 | 34,910,598.79 | 20,933,355.19 | 18,547,082.58 |
| (二)按所有权归属分类 | | | | |
| 归属于母公司股东的净利润 | 9,218,063.65 | 34,910,598.79 | 20,933,355.19 | 18,547,082.58 |
| 扣除非经常损益后的净利润 | 2,518,836.6 | 7,883,456.48 | 543,819.18 | 4,416,152.74 |
| 七、每股收益 | | | | |
| (一)基本每股收益 | 0.02 | 0.08 | 0.05 | 0.06 |
| (二)稀释每股收益 | 0.02 | 0.08 | 0.05 | 0.06 |
| 八、其他综合收益 | - | 628,950.39 | - | -49,303.28 |
| 归属于母公司股东的其他综合收益 | - | 628,950.39 | - | -49,303.28 |
| 九、综合收益总额 | 9,218,063.65 | 35,539,549.18 | 20,933,355.19 | 18,497,779.3 |
| 归属于母公司股东的综合收益总额 | 9,218,063.65 | 35,539,549.18 | 20,933,355.19 | 18,497,779.3 |
| 公告日期 | 2026-04-23 | 2026-03-31 | 2025-10-28 | 2025-08-01 |
| 审计意见(境内) | | 标准无保留意见 | | 标准无保留意见 |